{
  "patent_number": "US 6090382",
  "country": "US",
  "title": "Antibodies That Block Tumor Necrosis Factor Alpha (TNFα)",
  "original_title": "Human antibodies that bind human TNFα",
  "summary": "This 2000 patent describes specific human antibodies designed to strongly bind and neutralize a protein called TNFα, which is linked to inflammation and autoimmune diseases.",
  "what_it_does": "This patent describes specific human antibodies, or parts of them, that are engineered to latch onto a molecule called human tumor necrosis factor alpha (hTNFα). The key is how well and how long they stick: they must bind very tightly (dissociating with a K d of 1x10^-8 M or less) and stay attached for a significant time (dissociating with a K off rate constant of 1x10^-3 s^-1 or less). These binding characteristics allow the antibodies to effectively block the harmful activity of hTNFα, as shown by their ability to neutralize hTNFα's toxicity in lab tests (IC 50 of 1x10^-7 M or less). The patent also details specific sequences for parts of these antibodies, like the CDR3 regions of their light and heavy chains, which are crucial for binding. These antibodies can be used to detect hTNFα or to treat conditions where hTNFα causes problems, such as inflammatory diseases.",
  "what_it_does_not_cover": [
    "Antibodies that do not bind human TNFα.",
    "Antibodies that bind human TNFα but do not meet the specific binding affinity (K d) or dissociation rate (K off) thresholds.",
    "Antibodies that bind human TNFα but do not neutralize its cytotoxic activity in the specified L929 assay.",
    "Antibodies that are not human or are not derived from human sequences.",
    "Antibodies that bind to other molecules besides human TNFα."
  ],
  "filed": "1996-02-09",
  "granted": "2000-07-18",
  "expires": null,
  "status": "active",
  "holder": "BASF SE",
  "holder_url": "https://patentbrief.org/company/basf-se",
  "inventors": [
    {
      "name": "Alison J. Wilton",
      "url": "https://patentbrief.org/inventor/alison-j-wilton"
    },
    {
      "name": "John A. Mankovich",
      "url": "https://patentbrief.org/inventor/john-a-mankovich"
    },
    {
      "name": "Andrew J. Roberts",
      "url": "https://patentbrief.org/inventor/andrew-j-roberts"
    },
    {
      "name": "Hendricus R. J. M. Hoogenboom",
      "url": "https://patentbrief.org/inventor/hendricus-r-j-m-hoogenboom"
    },
    {
      "name": "Brian T. McGuinness",
      "url": "https://patentbrief.org/inventor/brian-t-mcguinness"
    },
    {
      "name": "Michael White",
      "url": "https://patentbrief.org/inventor/michael-white"
    },
    {
      "name": "Deborah J. Allen",
      "url": "https://patentbrief.org/inventor/deborah-j-allen"
    },
    {
      "name": "Paul Sakorafas",
      "url": "https://patentbrief.org/inventor/paul-sakorafas"
    },
    {
      "name": "Boris Labkovsky",
      "url": "https://patentbrief.org/inventor/boris-labkovsky"
    },
    {
      "name": "David Schoenhaut",
      "url": "https://patentbrief.org/inventor/david-schoenhaut"
    },
    {
      "name": "Tristan J. Vaughan",
      "url": "https://patentbrief.org/inventor/tristan-j-vaughan"
    },
    {
      "name": "Jochen G. Salfeld",
      "url": "https://patentbrief.org/inventor/jochen-g-salfeld"
    },
    {
      "name": "Zehra Kaymakcalan",
      "url": "https://patentbrief.org/inventor/zehra-kaymakcalan"
    }
  ],
  "times_cited": 361,
  "tags": [
    "biotech",
    "pharmaceutical",
    "biologic_drugs"
  ],
  "abstract": "Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 -8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 -3 sec -1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",
  "url": "https://patentbrief.org/patent/us/6090382/humira-adalimumab",
  "markdown_url": "https://patentbrief.org/patent/us/6090382/humira-adalimumab/md",
  "google_patents_url": "https://patents.google.com/patent/US6090382",
  "relatedPatents": []
}